<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00121966</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT00121966</nct_id>
  </id_info>
  <brief_title>South Danish Diabetes Study: Evaluation of the Antidiabetic Treatment of Type 2 Diabetes Mellitus</brief_title>
  <acronym>SDDS</acronym>
  <official_title>South Danish Diabetes Study: A Prospective Randomised Multi-Centre Study for the Evaluation of the Optimal Pharmacological Antidiabetic Treatment of Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Odense University Hospital</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is:&#xD;
&#xD;
        -  To investigate whether insulin aspart with meals is better than a standard treatment&#xD;
           with insulin NPH at bedtime, evaluated by HbA1c.&#xD;
&#xD;
      The secondary objectives of this study are:&#xD;
&#xD;
        -  To study if a combination treatment with metformin and/or rosiglitazone and insulin&#xD;
           aspart with meals is better than a standard treatment with insulin NPH combined with one&#xD;
           or more of the above oral antidiabetic drugs. According to the hypothesis, special focus&#xD;
           will be given to the treatment group with insulin aspart combined with metformin and&#xD;
           rosiglitazone. The treatment effect will be evaluated by HbA1c.&#xD;
&#xD;
        -  To examine the effects of the treatments on glucose metabolism and beta cell function,&#xD;
           evaluated by diurnal blood glucose, fasting plasma glucose, insulin, C-peptide, and&#xD;
           lactate.&#xD;
&#xD;
        -  To examine the effects of the treatments on cardiovascular risk factors evaluated by&#xD;
           serum lipid profiles, serum free fatty acids, urine albumin/creatinine ratio, and&#xD;
           electrocardiogram (ECG).&#xD;
&#xD;
        -  To quantify and describe the patients' subjective experiences of the two different&#xD;
           insulin treatments (quality of life assessment)&#xD;
&#xD;
        -  To examine patients with type 2 diabetes for the presence of variability in a series of&#xD;
           genes, which are known to or are assumed to:&#xD;
&#xD;
             -  affect the long term outcome;&#xD;
&#xD;
             -  determine the responsiveness to treatment with diet, exercise and drugs targeting&#xD;
                the known risk markers for late diabetic complications; and&#xD;
&#xD;
             -  after intervention, to analyse the complex interrelationships between genotypes and&#xD;
                clinical endpoints and the responsiveness to actual treatment modalities.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c following two years of treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>body weight</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting blood glucose</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diurnal blood glucose profiles (self monitored and continuously monitored)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting cholesterol (including HDL, LDL, and triglyceride)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>free fatty acids</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lactate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting insulin, proinsulin-C-peptide</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine glucose</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine albumin/creatinine ratio</measure>
  </secondary_outcome>
  <enrollment>400</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin NPH</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages between 30 and 70 years&#xD;
&#xD;
          -  Fasting C-peptide &gt;300 pmol/l&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 25 kg/m2&#xD;
&#xD;
          -  Diabetes for more than 2 years&#xD;
&#xD;
          -  Pharmacological antidiabetic treatment for more than 3 months&#xD;
&#xD;
          -  7.0%&lt;HbA1c&lt;12.0% at randomisation&#xD;
&#xD;
          -  Patient willing to sign informed consent&#xD;
&#xD;
          -  Fertile women: negative pregnancy test and use of oral or intra-uterine contraception&#xD;
             or depot gestagen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  S-creatinine &gt; 120 Î¼mol/l&#xD;
&#xD;
          -  History of intolerance to metformin or glitazones&#xD;
&#xD;
          -  S-ALAT/S-ASAT &gt; 2.5 x upper normal limit&#xD;
&#xD;
          -  Total cholesterol &gt; 10 mmol/l&#xD;
&#xD;
          -  Total triglyceride &gt; 8 mmol/l&#xD;
&#xD;
          -  Hemoglobin (Hb) &lt; normal range&#xD;
&#xD;
          -  Treatment with glitazone preceding 30 days New York Heart Association (NYHA)&#xD;
             functional class III or IV&#xD;
&#xD;
          -  Night work&#xD;
&#xD;
          -  Present or planned pregnancy&#xD;
&#xD;
          -  Poor vision impeding insulin administration&#xD;
&#xD;
          -  Unawareness of hypoglycaemia (complete or partly)&#xD;
&#xD;
          -  Mental illness or alcohol abuse&#xD;
&#xD;
          -  Clinically relevant major organ or systemic illness&#xD;
&#xD;
          -  Uncontrolled hypertension &gt;180/110 mmHg, systolic or diastolic&#xD;
&#xD;
          -  Steroid treatment&#xD;
&#xD;
          -  Severe lung disease&#xD;
&#xD;
          -  A history of malign disease&#xD;
&#xD;
          -  An expectation that the patient will not be collaborative or will not be able to&#xD;
             understand the character of this trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeppe Gram, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Esbjerg Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Research Center</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <study_first_submitted>July 8, 2005</study_first_submitted>
  <study_first_submitted_qc>July 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2005</study_first_posted>
  <last_update_submitted>June 18, 2008</last_update_submitted>
  <last_update_submitted_qc>June 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jeppe Gram/MD</name_title>
    <organization>Ribe County Hospital, Esbjerg, Denmark</organization>
  </responsible_party>
  <keyword>Type 2 diabetes</keyword>
  <keyword>Insulin Aspart</keyword>
  <keyword>Insulin NPH</keyword>
  <keyword>Metformin</keyword>
  <keyword>Rosiglitazone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Isophane Insulin, Human</mesh_term>
    <mesh_term>Insulin, Isophane</mesh_term>
    <mesh_term>Isophane insulin, beef</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

